Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Journal of Alzheimers Disease & Parkinsonism received 4334 citations as per Google Scholar report
Martha A. Brumfield, PhD, is President and Chief Executive Officer of Critical Path Institute, an Arizona-based non-profit (501(c)3). In this role, Brumfield leads the institute in its mission to catalyze the development of new tools to advance medical product innovation and regulatory science, which is accomplished by leading teams that share data, knowledge, and expertise resulting in sound, consensus-based science. Brumfield assumed the role of CEO after most recently serving as Critical Path Institute’s Director of International & Regulatory Programs. In that position, she helped guide international program development and provided regulatory expertise to consortia. She is also Professor, College of Pharmacy in the Department of Pharmacy Practice and Science at The University of Arizona.
Brumfield brings 20 years of experience from Pfizer Inc, most recently, as senior vice president of worldwide regulatory affairs and quality assurance. There, she led a global team that supported lifecycle pharmaceutical research, development and commercialization through creation and implementation of regulatory strategies and quality assurance oversight. Brumfield also played a key role in managing the broader company relationships with global regulators, trade associations, academics and others on regulatory policy issues. She served on corporate governance initiatives including the planning and implementation of mergers and acquisitions and led her departments through these periods of significant change.
She is President of the Board of Directors for the Regulatory Affairs Professional Society and chairs the Global Curriculum Coordinating Committee with FDA’s Office of International Policy which is developing a curriculum for regulators in developing countries. She is also active with global nonprofits, including the Regulatory Harmonization Institute and GlobalMD, where she delivers educational workshops on regulatory and clinical trial topics in Asia. She has served on and contributed to the Institute of Medicine consensus committees, which were commissioned by U.S. FDA focusing on global regulatory systems and on falsified and substandard drugs. She also serves on the Steering Committee of the Multi-Regional Clinical Trials Center of Harvard and Brigham and Women’s Hospital.
Brumfield earned a B.S. and an M.S. in chemistry from Virginia Commonwealth University, a Ph.D. in organic chemistry from the University of Maryland, and served as a post-doctoral fellow at the Rockefeller University.
neurology, organic chemistry, chemistry, regulatory systems, clinical trials
Diane Stephenson, Martha Brumfield, Klaus Romero, Janet Woodcock, Issam Zineh, Eric M Reiman, Caroline Tanner, Richard Mohs, Walter Koroshetz, Timothy Nicholas, Lisa J Bain, Derek Hill, Les Shaw, Johan Luthman, Michael Ropacki, Richard Meibach, Peter Loupos, Ken Marek, James Hendrix, Eric Karran, George Vradenburg, Keiju Motohashi, Jesse M Cedarbaum and Mark Forrest Gordon
Conference Proceeding: J Alzheimers Dis Parkinsonism 2015, 5:183
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals